References
- McDuffie FC. Morbidity impact of rheumatoid arthritis on society. Am J Med 1985: 78(1A):1–5
- Fries JF. Safety issues related to DMARD therapy. J Rheumatol Suppl 1990:25:14–7
- Pincus T, Callahan LF. Reassessment of twelve traditional paradigms concerning the diagnosis, prevalence, morbidity and mortality of rheumatoid arthritis. Scand J Rheumatol Suppl 1989:79:67–96
- Sigler JW, Bluhm GB, Duncan H, et al. Gold salts in the treatment of rheumatoid arthritis: a double-blind study. Ann Intern Med 1974: 80(1):21–6
- Adams CH, Cecil RL. Gold therapy in early rheumatoid arthritis. Ann Intern Med 1950: 33(0:163–73
- Sanibrook PN, Browne CD, Champion GD, et al. Terminations of treatment with gold sodium thiomalate in rheumatoid arthritis. J Rheumatol 1982: 9(6): 932–4
- Richter JA, Runge LA, Pinals RS, et al. Analysis of treatment terminations with gold and antimalarial compounds in rheumatoid arthritis. J Rheumatol 1980: 7(2): 153–9
- Ward J R, Williams HJ, Egger MJ, et al. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1983: 26(11): 1303–15
- Kimberly RP. Steroids. Curr Opin Rheumatol 1990: 2(3): 510–6
- Weiss MM. Corticosteroids in rheumatoid arthritis. Semin Arthritis Rheum 1989: 19(1): 9–21
- Reid IR, King AR, Alexander CJ, et al. Prevention of steroid-induced osteoporosis with (3- amino-l-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1988: 1(8578): 143–6
- McCune WJ, Bayliss GE. Immunosuppressive drug therapy. Curr Opin Rheumatol 1990: 2(3): 497–505
- Fehlauer CS, Carson CW, Cannon GW, et al. Methotrexate therapy in rheumatoid arthritis: 2-year retrospective followup study. J Rheumatol 1989: 16(3): 307–12
- Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990: 33(1): 9–18
- Brick JE, Moreland LW, AI-Kawas F, et al. Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients. Semin Arthritis Rheum 1989: 19(1): 31–44
- Kremer JM, Lee RG, Tolman KG. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy: a prospective studv with baseline and sequential biopsy samples. Arthritis Rheum 1989: 32(2): 121–7
- Shergy WJ, Polisson RP, Caldwell DS, et al. Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. Am J Med 1988: 85(6): 771–4
- Lightfoot RW. Treatment of rheumatoid arthritis. In: McCarty DJ, ed. Arthritis and allied conditions: a textbook of rheumatology. 11th ed. Philadelphia: Lea & Febiger, 1989: 772–82
- Kujala GA, Shamma'a JM, Chang WL, et al. Hepatitis with bridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking methotrexate. Arthritis Rheum 1990: 33(7): 1037–41
- Katz WA. Patient selection. J Rheumatol Suppl 1990: 25: 39–41
- Jaffe IA. Combination therapy of rheumatoid arthritis: rationale and overview. J Rheumatol Suppl 1990: 25: 24–7
- Chatham WW, Williams GV, Moreland LW, et al. Intraarticular (IA) injections: should we rest the joints (JTS). Arthritis Rheum 1989: 32 (Suppl 1): R45